Introduction

We need your help!


Myeloma Canada is seeking input from people impacted by multiple myeloma regarding anitocabtagene autoleucel (anito-cel), a CAR T-cell therapy soon undergoing reimbursement review for a new indication at Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS)
Sharing your experience can help decision-makers better understand how access to anito-cel could benefit Canadians with myeloma.


This survey is intended for all individuals with myeloma and/or their caregivers, if you do not meet the criteria below, you will be asked questions about your experience with/knowledge of CAR T-cell therapy, and linked to other ongoing surveys you are eligible for:

To be eligible for anito-cel
  • Adults with relapsed/refractory multiple myeloma who have received at least 3 prior lines of therapy; including a proteasome inhibitor (PI) an immunomodulatory agent (IMiD); AND and anti-CD 38 monoclonal antibody.
OR
  • Have received or are currently receiving treatment with anitocabtagene autoeleucel;
OR
  • Have received or are currently receiving treatment with a different CAR T-cell therapy

This survey should only take around 10 minutes of your time. We ask that the survey please be completed by November 16, 2026, 11:59 PM EST.


If you have any questions, please write to contact@myeloma.ca and indicate “CAR T Survey” in the subject line.


Thank you for your participation and helping your fellow Canadians impacted by myeloma!
( Privacy & Cookie Notice

T